{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:55:48Z","timestamp":1775033748289,"version":"3.50.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004321","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004162","name":"Meath Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004162","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002081","name":"Irish Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002081","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Pfizer Endocrine Care"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glucocorticoid therapy is the most common cause of iatrogenic osteoporosis. Less is known regarding the effect of glucocorticoids when used as replacement therapy on bone remodelling in patients with adrenal insufficiency. Enhanced intracellular conversion of inactive cortisone to active cortisol, by 11 beta-hydroxysteroid dehydrogenase type 1(11\u03b2-HSD1) and other enzymes leading to alterations in glucocorticoid metabolism, may contribute to a deleterious effect on bone health in this patient group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Study design: An open crossover prospective study randomizing ten hypopituitary men, with severe ACTH deficiency, to three commonly used hydrocortisone dose regimens.<\/jats:p>\n                    <jats:p>Measurements: Following 6\u2009weeks of each regimen, patients underwent 24-h serum cortisol\/cortisone sampling, measurement of bone turnover markers, and a 24-h urine collection for measurement of urinary steroid metabolites by gas chromatography-mass spectrometry (GC-MS). Serum cortisone and cortisol were analysed by liquid chromatography-mass spectrometry (LC-MS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Dose-related and circadian variations in serum cortisone were seen to parallel those for cortisol, indicating conversion of ingested hydrocortisone to cortisone. The median area under the curve (AUC) of serum cortisone was significantly higher in patients on dose A (20\u2009mg\/10\u2009mg) [670.5 (IQR 621\u2013809.2)] compared to those on dose C (10\u2009mg\/5\u2009mg) [562.8 (IQR 520.1\u2013619.6),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01]. A negative correlation was observed between serum cortisone and bone formation markers, OC [1\u201349] (\n                      <jats:italic>r<\/jats:italic>\n                      \u00a0=\u2009\u2212\u20090.42,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03), and PINP (\n                      <jats:italic>r<\/jats:italic>\n                      \u00a0=\u2009\u2212\u20090.49,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.01). There was a negative correlation between the AUC of night-time serum cortisone levels with the bone formation marker, OC [1\u201349] (\n                      <jats:italic>r<\/jats:italic>\n                      \u00a0=\u2009\u2212\u20090.41,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.03) but there were no significant correlations between day-time serum cortisone or cortisol with bone turnover markers. There was a negative correlation between total urinary cortisol metabolites and the bone formation markers, PINP (\n                      <jats:italic>r<\/jats:italic>\n                      \u00a0=\u2009\u2212\u20090.39,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04), and OC [1\u201349] (\n                      <jats:italic>r<\/jats:italic>\n                      \u00a0=\u2009\u2212\u20090.35,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.06).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Serum cortisol and cortisone and total urinary corticosteroid metabolites are negatively associated with bone turnover markers in patients receiving replacement doses of hydrocortisone, with nocturnal glucocorticoid exposure having a potentially greater influence on bone turnover.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Irish Medicines Board Clinical Trial Number \u2013 CT900\/459\/1 and EudraCT Number \u2013\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2007-005018-37\">2007-005018-37<\/jats:ext-link>\n                      . Registration date: 07-09-2007.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12902-020-00633-1","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T22:03:06Z","timestamp":1602280986000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The contribution of serum cortisone and glucocorticoid metabolites to detrimental bone health in patients receiving hydrocortisone therapy"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9740-7621","authenticated-orcid":false,"given":"Rosemary","family":"Dineen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy-Ann","family":"Behan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grainne","family":"Kelleher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Hannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer J.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bairbre","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian G.","family":"Keevil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Tormey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diarmuid","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malachi J.","family":"McKenna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wiebke","family":"Arlt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amar","family":"Agha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Sherlock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,10]]},"reference":[{"issue":"2","key":"633_CR1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.7861\/clinmedicine.8-2-211","volume":"8","author":"W Arlt","year":"2008","unstructured":"Arlt W. Adrenal insufficiency. Clin Med (London, England). 2008;8(2):211\u20135.","journal-title":"Clin Med (London, England)"},{"issue":"3","key":"633_CR2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1046\/j.1365-2265.1997.1340955.x","volume":"46","author":"TA Howlett","year":"1997","unstructured":"Howlett TA. An assessment of optimal hydrocortisone replacement therapy. Clin Endocrinol. 1997;46(3):263\u20138.","journal-title":"Clin Endocrinol"},{"issue":"3","key":"633_CR3","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/j.1365-2265.2004.02106.x","volume":"61","author":"PM Mah","year":"2004","unstructured":"Mah PM, Jenkins RC, Rostami-Hodjegan A, Newell-Price J, Doane A, Ibbotson V, et al. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol. 2004;61(3):367\u201375.","journal-title":"Clin Endocrinol"},{"issue":"9","key":"633_CR4","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1177\/014107688808100906","volume":"81","author":"RW Groves","year":"1988","unstructured":"Groves RW, Toms GC, Houghton BJ, Monson JP. Corticosteroid replacement therapy: twice or thrice daily? J R Soc Med. 1988;81(9):514\u20136.","journal-title":"J R Soc Med"},{"issue":"4","key":"633_CR5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/j.1365-2265.2011.04074.x","volume":"75","author":"LA Behan","year":"2011","unstructured":"Behan LA, Rogers B, Hannon MJ, O'Kelly P, Tormey W, Smith D, et al. Optimizing glucocorticoid replacement therapy in severely adrenocorticotropin-deficient hypopituitary male patients. Clin Endocrinol. 2011;75(4):505\u201313.","journal-title":"Clin Endocrinol"},{"issue":"2","key":"633_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/joim.12162","volume":"275","author":"ES Husebye","year":"2014","unstructured":"Husebye ES, Allolio B, Arlt W, Badenhoop K, Bensing S, Betterle C, et al. Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J Intern Med. 2014;275(2):104\u201315.","journal-title":"J Intern Med"},{"issue":"6","key":"633_CR7","doi-asserted-by":"publisher","first-page":"R165","DOI":"10.1530\/EJE-13-0450","volume":"169","author":"A Grossman","year":"2013","unstructured":"Grossman A, Johannsson G, Quinkler M, Zelissen P. Therapy of endocrine disease: perspectives on the management of adrenal insufficiency: clinical insights from across Europe. Eur J Endocrinol. 2013;169(6):R165\u201375.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"633_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/cen.12603","volume":"82","author":"G Johannsson","year":"2015","unstructured":"Johannsson G, Falorni A, Skrtic S, Lennernas H, Quinkler M, Monson JP, et al. Adrenal insufficiency: review of clinical outcomes with current glucocorticoid replacement therapy. Clin Endocrinol. 2015;82(1):2\u201311.","journal-title":"Clin Endocrinol"},{"issue":"10","key":"633_CR9","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","volume":"18","author":"E Canalis","year":"2007","unstructured":"Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007;18(10):1319\u201328.","journal-title":"Osteoporos Int"},{"issue":"2","key":"633_CR10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.bone.2006.02.005","volume":"39","author":"A Angeli","year":"2006","unstructured":"Angeli A, Guglielmi G, Dovio A, Capelli G, de Feo D, Giannini S, et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone. 2006;39(2):253\u20139.","journal-title":"Bone."},{"issue":"3","key":"633_CR11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.7326\/0003-4819-120-3-199402010-00005","volume":"120","author":"PM Zelissen","year":"1994","unstructured":"Zelissen PM, Croughs RJ, van Rijk PP, Raymakers JA. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann Intern Med. 1994;120(3):207\u201310.","journal-title":"Ann Intern Med"},{"issue":"3","key":"633_CR12","first-page":"179","volume":"61","author":"F Heureux","year":"2000","unstructured":"Heureux F, Maiter D, Boutsen Y, Devogelaer JP, Jamart J, Donckier J. Evaluation of corticosteroid replacement therapy and its effect on bones in Addison's disease. Ann Endocrinol. 2000;61(3):179\u201383.","journal-title":"Ann Endocrinol"},{"issue":"5","key":"633_CR13","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1046\/j.1365-2265.2003.01761.x","volume":"58","author":"E Jodar","year":"2003","unstructured":"Jodar E, Valdepenas MP, Martinez G, Jara A, Hawkins F. Long-term follow-up of bone mineral density in Addison's disease. Clin Endocrinol. 2003;58(5):617\u201320.","journal-title":"Clin Endocrinol"},{"issue":"1","key":"633_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1210\/jc.2011-2036","volume":"97","author":"KR Koetz","year":"2012","unstructured":"Koetz KR, Ventz M, Diederich S, Quinkler M. Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy. J Clin Endocrinol Metab. 2012;97(1):85\u201392.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"633_CR15","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1530\/EJE-08-0880","volume":"160","author":"K Lovas","year":"2009","unstructured":"Lovas K, Gjesdal CG, Christensen M, Wolff AB, Almas B, Svartberg J, et al. Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. Eur J Endocrinol. 2009;160(6):993\u20131002.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"633_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0169-6009(08)80158-4","volume":"26","author":"MA Valero","year":"1994","unstructured":"Valero MA, Leon M, Ruiz Valdepenas MP, Larrodera L, Lopez MB, Papapietro K, et al. Bone density and turnover in Addison\u2019s disease: effect of glucocorticoid treatment. Bone Mineral. 1994;26(1):9\u201317.","journal-title":"Bone Mineral"},{"issue":"6","key":"633_CR17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s001980050251","volume":"10","author":"GD Braatvedt","year":"1999","unstructured":"Braatvedt GD, Joyce M, Evans M, Clearwater J, Reid IR. Bone mineral density in patients with treated Addison\u2019s disease. Osteoporos Int. 1999;10(6):435\u201340.","journal-title":"Osteoporos Int"},{"issue":"3","key":"633_CR18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1046\/j.1365-2265.1997.780907.x","volume":"46","author":"SR Peacey","year":"1997","unstructured":"Peacey SR, Guo CY, Robinson AM, Price A, Giles MA, Eastell R, et al. Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin Endocrinol. 1997;46(3):255\u201361.","journal-title":"Clin Endocrinol"},{"issue":"Suppl 3","key":"633_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1046\/j.1365-2362.2000.0300s3055.x","volume":"30","author":"M Wichers","year":"2000","unstructured":"Wichers M, Springer W, Bidlingmaier F, Klingmuller D. How hydrocortisone substitution influences the quality of life and the bone metabolism of patients with secondary hypocortisolism. Eur J Clin Investig. 2000;30(Suppl 3):55\u20137.","journal-title":"Eur J Clin Investig"},{"issue":"1","key":"633_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1530\/EJE-13-0596","volume":"170","author":"LA Behan","year":"2014","unstructured":"Behan LA, Kelleher G, Hannon MJ, Brady JJ, Rogers B, Tormey W, et al. Low-dose hydrocortisone replacement therapy is associated with improved bone remodelling balance in hypopituitary male patients. Eur J Endocrinol. 2014;170(1):141\u201350.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"633_CR21","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1365-2265.2005.02281.x","volume":"62","author":"MS Cooper","year":"2005","unstructured":"Cooper MS, Syddall HE, Fall CH, Wood PJ, Stewart PM, Cooper C, et al. Circulating cortisone levels are associated with biochemical markers of bone formation and lumbar spine BMD: the Hertfordshire cohort study. Clin Endocrinol. 2005;62(6):692\u20137.","journal-title":"Clin Endocrinol"},{"issue":"3","key":"633_CR22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s00223-004-0270-2","volume":"77","author":"RM Reynolds","year":"2005","unstructured":"Reynolds RM, Dennison EM, Walker BR, Syddall HE, Wood PJ, Andrew R, et al. Cortisol secretion and rate of bone loss in a population-based cohort of elderly men and women. Calcif Tissue Int. 2005;77(3):134\u20138.","journal-title":"Calcif Tissue Int"},{"issue":"9","key":"633_CR23","doi-asserted-by":"publisher","first-page":"M479","DOI":"10.1093\/gerona\/54.9.M479","volume":"54","author":"H Raff","year":"1999","unstructured":"Raff H, Raff JL, Duthie EH, Wilson CR, Sasse EA, Rudman I, et al. Elevated salivary cortisol in the evening in healthy elderly men and women: correlation with bone mineral density. J Gerontol A Biol Sci Med Sci. 1999;54(9):M479\u201383.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"6","key":"633_CR24","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00223-001-2085-8","volume":"70","author":"K Brooke-Wavell","year":"2002","unstructured":"Brooke-Wavell K, Clow A, Ghazi-Noori S, Evans P, Hucklebridge F. Ultrasound measures of bone and the diurnal free cortisol cycle: a positive association with the awakening cortisol response in healthy premenopausal women. Calcif Tissue Int. 2002;70(6):463\u20138.","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"633_CR25","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1530\/EJE-11-0957","volume":"166","author":"G Osella","year":"2012","unstructured":"Osella G, Ventura M, Ardito A, Allasino B, Termine A, Saba L, et al. Cortisol secretion, bone health, and bone loss: a cross-sectional and prospective study in normal non-osteoporotic women in the early postmenopausal period. Eur J Endocrinol. 2012;166(5):855\u201360.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"633_CR26","first-page":"1410","volume":"74","author":"HK Nielsen","year":"1992","unstructured":"Nielsen HK, Brixen K, Kassem M, Charles P, Mosekilde L. Inhibition of the morning cortisol peak abolishes the expected morning decrease in serum osteocalcin in normal males: evidence of a controlling effect of serum cortisol on the circadian rhythm in serum osteocalcin. J Clin Endocrinol Metab. 1992;74(6):1410\u20134.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"633_CR27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S8756-3282(97)00039-2","volume":"21","author":"A Schlemmer","year":"1997","unstructured":"Schlemmer A, Hassager C, Alexandersen P, Fledelius C, Pedersen BJ, Kristensen IO, et al. Circadian variation in bone resorption is not related to serum cortisol. Bone. 1997;21(1):83\u20138.","journal-title":"Bone."},{"issue":"3","key":"633_CR28","first-page":"751","volume":"83","author":"HM Heshmati","year":"1998","unstructured":"Heshmati HM, Riggs BL, Burritt MF, McAlister CA, Wollan PC, Khosla S. Effects of the circadian variation in serum cortisol on markers of bone turnover and calcium homeostasis in normal postmenopausal women. J Clin Endocrinol Metab. 1998;83(3):751\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"633_CR29","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaut.2018.05.010","volume":"92","author":"RS Hardy","year":"2018","unstructured":"Hardy RS, Fenton C, Croft AP, Naylor AJ, Begum R, Desanti G, et al. 11 Beta-hydroxysteroid dehydrogenase type 1 regulates synovitis, joint destruction, and systemic bone loss in chronic polyarthritis. J Autoimmun. 2018;92:104\u201313.","journal-title":"J Autoimmun"},{"issue":"3","key":"633_CR30","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S8756-3282(00)00344-6","volume":"27","author":"MS Cooper","year":"2000","unstructured":"Cooper MS, Walker EA, Bland R, Fraser WD, Hewison M, Stewart PM. Expression and functional consequences of 11beta-hydroxysteroid dehydrogenase activity in human bone. Bone. 2000;27(3):375\u201381.","journal-title":"Bone."},{"issue":"3","key":"633_CR31","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1677\/joe.0.1610455","volume":"161","author":"R Bland","year":"1999","unstructured":"Bland R, Worker CA, Noble BS, Eyre LJ, Bujalska IJ, Sheppard MC, et al. Characterization of 11beta-hydroxysteroid dehydrogenase activity and corticosteroid receptor expression in human osteosarcoma cell lines. J Endocrinol. 1999;161(3):455\u201364.","journal-title":"J Endocrinol"},{"issue":"6","key":"633_CR32","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.bone.2009.07.080","volume":"45","author":"JY Hwang","year":"2009","unstructured":"Hwang JY, Lee SH, Kim GS, Koh JM, Go MJ, Kim YJ, et al. HSD11B1 polymorphisms predicted bone mineral density and fracture risk in postmenopausal women without a clinically apparent hypercortisolemia. Bone. 2009;45(6):1098\u2013103.","journal-title":"Bone."},{"issue":"3\u20135","key":"633_CR33","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jsbmb.2007.09.018","volume":"108","author":"S Pierotti","year":"2008","unstructured":"Pierotti S, Gandini L, Lenzi A, Isidori AM. Pre-receptorial regulation of steroid hormones in bone cells: insights on glucocorticoid-induced osteoporosis. J Steroid Biochem Mol Biol. 2008;108(3\u20135):292\u20139.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"6","key":"633_CR34","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1530\/EJE-15-1187","volume":"174","author":"LA Behan","year":"2016","unstructured":"Behan LA, Carmody D, Rogers B, Hannon MJ, Davenport C, Tormey W, et al. Low-dose hydrocortisone replacement is associated with improved arterial stiffness index and blood pressure dynamics in severely adrenocorticotrophin-deficient hypopituitary male patients. Eur J Endocrinol. 2016;174(6):791\u20139.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"633_CR35","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1530\/EJE-15-0490","volume":"173","author":"M Sherlock","year":"2015","unstructured":"Sherlock M, Behan LA, Hannon MJ, Alonso AA, Thompson CJ, Murray RD, et al. The modulation of corticosteroid metabolism by hydrocortisone therapy in patients with hypopituitarism increases tissue glucocorticoid exposure. Eur J Endocrinol. 2015;173(5):583\u201393.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"633_CR36","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/cen.13267","volume":"86","author":"RD Murray","year":"2017","unstructured":"Murray RD, Ekman B, Uddin S, Marelli C, Quinkler M, Zelissen PM. Management of glucocorticoid replacement in adrenal insufficiency shows notable heterogeneity - data from the EU-AIR. Clin Endocrinol. 2017;86(3):340\u20136.","journal-title":"Clin Endocrinol"},{"key":"633_CR37","volume-title":"The Bart's endocrine protocols: Churchill Livingstone","author":"PJ Trainer","year":"1995","unstructured":"Trainer PJ, Besser GM. The Bart's endocrine protocols: Churchill Livingstone; 1995."},{"issue":"Pt 4","key":"633_CR38","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1177\/0004563212473448","volume":"50","author":"LJ Owen","year":"2013","unstructured":"Owen LJ, Adaway JE, Davies S, Neale S, El-Farhan N, Ducroq D, et al. Development of a rapid assay for the analysis of serum cortisol and its implementation into a routine service laboratory. Ann Clin Biochem. 2013;50(Pt 4):345\u201352.","journal-title":"Ann Clin Biochem"},{"issue":"5","key":"633_CR39","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1046\/j.1365-2265.1996.00853.x","volume":"45","author":"M Palermo","year":"1996","unstructured":"Palermo M, Shackleton CH, Mantero F, Stewart PM. Urinary free cortisone and the assessment of 11 beta-hydroxysteroid dehydrogenase activity in man. Clin Endocrinol. 1996;45(5):605\u201311.","journal-title":"Clin Endocrinol"},{"issue":"12","key":"633_CR40","doi-asserted-by":"publisher","first-page":"3775","DOI":"10.1210\/jc.2011-1565","volume":"96","author":"W Arlt","year":"2011","unstructured":"Arlt W, Biehl M, Taylor AE, Hahner S, Libe R, Hughes BA, et al. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab. 2011;96(12):3775\u201384.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"633_CR41","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1210\/jc.2009-0837","volume":"94","author":"DA Vassiliadi","year":"2009","unstructured":"Vassiliadi DA, Barber TM, Hughes BA, McCarthy MI, Wass JA, Franks S, et al. Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2009;94(9):3558\u201366.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"633_CR42","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.bone.2013.09.010","volume":"57","author":"J Michelsen","year":"2013","unstructured":"Michelsen J, Wallaschofski H, Friedrich N, Spielhagen C, Rettig R, Ittermann T, et al. Reference intervals for serum concentrations of three bone turnover markers for men and women. Bone. 2013;57(2):399\u2013404.","journal-title":"Bone."},{"issue":"5","key":"633_CR43","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/000456328001700502","volume":"17","author":"JD Few","year":"1980","unstructured":"Few JD, Cashmore GC. Plasma cortisone in man: its determination, physiological variation, and significance. Ann Clin Biochem. 1980;17(5):227\u201332.","journal-title":"Ann Clin Biochem"},{"issue":"8 Pt 1","key":"633_CR44","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1093\/clinchem\/43.8.1397","volume":"43","author":"G Morineau","year":"1997","unstructured":"Morineau G, Boudi A, Barka A, Gourmelen M, Degeilh F, Hardy N, et al. Radioimmunoassay of cortisone in serum, urine, and saliva to assess the status of the cortisol-cortisone shuttle. Clin Chem. 1997;43(8 Pt 1):1397\u2013407.","journal-title":"Clin Chem"},{"issue":"13\u201314","key":"633_CR45","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.clinbiochem.2016.04.009","volume":"49","author":"BG Keevil","year":"2016","unstructured":"Keevil BG. LC-MS\/MS analysis of steroids in the clinical laboratory. Clin Biochem. 2016;49(13\u201314):989\u201397.","journal-title":"Clin Biochem"},{"key":"633_CR46","first-page":"787483","volume":"2014","author":"S Lee","year":"2014","unstructured":"Lee S, Lim HS, Shin HJ, Kim SA, Park J, Kim HC, et al. Simultaneous determination of cortisol and cortisone from human serum by liquid chromatography-tandem mass spectrometry. J Anal Methods Chem. 2014;2014:787483.","journal-title":"J Anal Methods Chem"},{"issue":"3","key":"633_CR47","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/0009-8981(75)90418-0","volume":"61","author":"A Angeli","year":"1975","unstructured":"Angeli A, Bisbocci D, Melo F, Frairia R, Gaidano GP. Relative competition of corticosterone, cortisol, cortisone, 11-dexycortisol and prednisolone with (1,2-3H)-cortisol in various protein-binding radioassay systems. Clin Chimica Acta. 1975;61(3):279\u201386.","journal-title":"Clin Chimica Acta"},{"issue":"4","key":"633_CR48","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1210\/jc.2015-3694","volume":"101","author":"M Debono","year":"2016","unstructured":"Debono M, Harrison RF, Whitaker MJ, Eckland D, Arlt W, Keevil BG, et al. Salivary cortisone reflects cortisol exposure under physiological conditions and after hydrocortisone. J Clin Endocrinol Metab. 2016;101(4):1469\u201377.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"633_CR49","doi-asserted-by":"publisher","first-page":"4172","DOI":"10.1172\/JCI63377","volume":"122","author":"TC Brennan-Speranza","year":"2012","unstructured":"Brennan-Speranza TC, Henneicke H, Gasparini SJ, Blankenstein KI, Heinevetter U, Cogger VC, et al. Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism. J Clin Invest. 2012;122(11):4172\u201389.","journal-title":"J Clin Invest"},{"issue":"8","key":"633_CR50","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1089\/dna.1997.16.919","volume":"16","author":"T Meyer","year":"1997","unstructured":"Meyer T, Gustafsson JA, Carlstedt-Duke J. Glucocorticoid-dependent transcriptional repression of the osteocalcin gene by competitive binding at the TATA box. DNA Cell Biol. 1997;16(8):919\u201327.","journal-title":"DNA Cell Biol"},{"issue":"2","key":"633_CR51","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1210\/jcem-72-2-382","volume":"72","author":"MF Prummel","year":"1991","unstructured":"Prummel MF, Wiersinga WM, Lips P, Sanders GT, Sauerwein HP. The course of biochemical parameters of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab. 1991;72(2):382\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"633_CR52","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1210\/jcem-62-2-379","volume":"62","author":"IR Reid","year":"1986","unstructured":"Reid IR, Chapman GE, Fraser TR, Davies AD, Surus AS, Meyer J, et al. Low serum osteocalcin levels in glucocorticoid-treated asthmatics. J Clin Endocrinol Metab. 1986;62(2):379\u201383.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"633_CR53","first-page":"487","volume":"74","author":"R Eastell","year":"1992","unstructured":"Eastell R, Calvo MS, Burritt MF, Offord KP, Russell RG, Riggs BL. Abnormalities in circadian patterns of bone resorption and renal calcium conservation in type I osteoporosis. J Clin Endocrinol Metab. 1992;74(3):487\u201394.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"633_CR54","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1210\/jcem-60-4-736","volume":"60","author":"CM Gundberg","year":"1985","unstructured":"Gundberg CM, Markowitz ME, Mizruchi M, Rosen JF. Osteocalcin in human serum: a circadian rhythm. J Clin Endocrinol Metab. 1985;60(4):736\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"633_CR55","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1210\/jcem-67-5-1025","volume":"67","author":"HK Nielsen","year":"1988","unstructured":"Nielsen HK, Charles P, Mosekilde L. The effect of single oral doses of prednisone on the circadian rhythm of serum osteocalcin in normal subjects. J Clin Endocrinol Metab. 1988;67(5):1025\u201330.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"633_CR56","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/cen.14149","volume":"92","author":"G Riehl","year":"2019","unstructured":"Riehl G, Reisch N, Roehle R, vander Grinten HC, Falhammar H, Quinkler M. Bone mineral density and fractures in congenital adrenal hyperplasia: findings from the dsd-LIFE study. Clin Endocrinol. 2019;92(4):284.","journal-title":"Clin Endocrinol"},{"issue":"8","key":"633_CR57","doi-asserted-by":"publisher","first-page":"3874","DOI":"10.1210\/jc.2003-022025","volume":"88","author":"MS Cooper","year":"2003","unstructured":"Cooper MS, Blumsohn A, Goddard PE, Bartlett WA, Shackleton CH, Eastell R, et al. 11beta-hydroxysteroid dehydrogenase type 1 activity predicts the effects of glucocorticoids on bone. J Clin Endocrinol Metab. 2003;88(8):3874\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"633_CR58","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.2337\/db08-0495","volume":"57","author":"JW Tomlinson","year":"2008","unstructured":"Tomlinson JW, Finney J, Gay C, Hughes BA, Hughes SV, Stewart PM. Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity. Diabetes. 2008;57(10):2652\u201360.","journal-title":"Diabetes."},{"issue":"1","key":"633_CR59","first-page":"109","volume":"39","author":"K Shimodaira","year":"1996","unstructured":"Shimodaira K, Fujikawa H, Okura F, Shimizu Y, Saito H, Yanaihara T. Osteoblast cells (MG-63 and HOS) have aromatase and 5 alpha-reductase activities. Biochem Mol Biol Int. 1996;39(1):109\u201316.","journal-title":"Biochem Mol Biol Int"},{"issue":"10","key":"633_CR60","doi-asserted-by":"publisher","first-page":"e0140598","DOI":"10.1371\/journal.pone.0140598","volume":"10","author":"D Robinson","year":"2015","unstructured":"Robinson D, Garmo H, Stattin P, Michaelsson K. Risk of fractures and falls during and after 5-alpha Reductase inhibitor use: a Nationwide cohort study. PLoS One. 2015;10(10):e0140598.","journal-title":"PLoS One"},{"issue":"6","key":"633_CR61","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/j.1365-2796.2003.01227.x","volume":"254","author":"PC Souverein","year":"2003","unstructured":"Souverein PC, Van Staa TP, Egberts AC, De la Rosette JJ, Cooper C, Leufkens HG. Use of alpha-blockers and the risk of hip\/femur fractures. J Intern Med. 2003;254(6):548\u201354.","journal-title":"J Intern Med"},{"issue":"4","key":"633_CR62","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/cen.12599","volume":"82","author":"WL Lin","year":"2015","unstructured":"Lin WL, Hsieh YW, Lin CL, Sung FC, Wu CH, Kao CH. A population-based nested case-control study: the use of 5-alpha-reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia. Clin Endocrinol. 2015;82(4):503\u20138.","journal-title":"Clin Endocrinol"},{"issue":"14","key":"633_CR63","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1001\/jama.300.14.1660","volume":"300","author":"SJ Jacobsen","year":"2008","unstructured":"Jacobsen SJ, Cheetham TC, Haque R, Shi JM, Loo RK. Association between 5-alpha reductase inhibition and risk of hip fracture. JAMA. 2008;300(14):1660\u20134.","journal-title":"JAMA."}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-020-00633-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-020-00633-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-020-00633-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T17:09:32Z","timestamp":1633885772000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-020-00633-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,10]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["633"],"URL":"https:\/\/doi.org\/10.1186\/s12902-020-00633-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-17423\/v1","asserted-by":"object"}]},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,10]]},"assertion":[{"value":"7 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Beaumont Hospital Research Ethics Committee, Dublin, Ireland. Patients were recruited from the Pituitary Clinic at Beaumont Hospital, Dublin, and gave informed written consent. The study adheres to CONSORT guidelines.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that no conflict of interest could be perceived as prejudicing the impartiality of the research reported.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"154"}}